Pliant Therapeutics Terminates Material Definitive Agreement
Ticker: PLRX · Form: 8-K · Filed: Oct 20, 2025 · CIK: 1746473
| Field | Detail |
|---|---|
| Company | Pliant Therapeutics, Inc. (PLRX) |
| Form Type | 8-K |
| Filed Date | Oct 20, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $32.4 m, $150 million, $30 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement-termination
Related Tickers: PLRX
TL;DR
PLRX terminated a big deal, watch for news.
AI Summary
Pliant Therapeutics, Inc. reported the termination of a material definitive agreement on October 14, 2025. The company, incorporated in Delaware with its principal executive offices in South San Francisco, CA, filed this 8-K report on October 20, 2025.
Why It Matters
The termination of a material definitive agreement can signal a shift in the company's strategic partnerships or contractual obligations, potentially impacting its operations and future plans.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement can introduce uncertainty regarding the company's business strategy and financial outlook.
Key Players & Entities
- PLIANT THERAPEUTICS, INC. (company) — Registrant
- October 14, 2025 (date) — Date of earliest event reported
- October 20, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- South San Francisco, CA (location) — Principal Executive Offices
- 001-39303 (filing_id) — Commission File Number
- 47-4272481 (tax_id) — IRS Employer Identification No.
FAQ
What specific material definitive agreement was terminated by Pliant Therapeutics, Inc.?
The filing states that a material definitive agreement was terminated, but does not specify which agreement it was.
What is the effective date of the termination of the material definitive agreement?
The earliest event reported, which is the termination of the material definitive agreement, occurred on October 14, 2025.
When did Pliant Therapeutics, Inc. file this 8-K report?
Pliant Therapeutics, Inc. filed this 8-K report on October 20, 2025.
In which state is Pliant Therapeutics, Inc. incorporated?
Pliant Therapeutics, Inc. is incorporated in Delaware.
What is the business address of Pliant Therapeutics, Inc.?
The business address of Pliant Therapeutics, Inc. is 331 Oyster Point Blvd., South San Francisco, CA 94080.
Filing Stats: 582 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2025-10-20 16:31:12
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share PLRX The Nasdaq Stock Mar
- $32.4 m — y") completed a voluntary prepayment of $32.4 million, representing all outstanding pri
- $150 million — m loans up to an aggregate principal of $150 million (the "Term Loans"). Under the Loan Agre
- $30 million — he Loan Agreement, the Company borrowed $30 million. The Term Loans accrued interest at a f
Filing Documents
- d14014d8k.htm (8-K) — 26KB
- 0001193125-25-243619.txt ( ) — 170KB
- plrx-20251014.xsd (EX-101.SCH) — 4KB
- plrx-20251014_def.xml (EX-101.DEF) — 13KB
- plrx-20251014_lab.xml (EX-101.LAB) — 22KB
- plrx-20251014_pre.xml (EX-101.PRE) — 14KB
- d14014d8k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. PLIANT THERAPEUTICS, INC. Date: October 20, 2025 By: /s/ Keith Cummings Keith Cummings, M.D., MBA Chief Financial Officer